Sherri Machele Donat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sherri Machele Donat has a total of 310 co-authors. Here are the top co-authors by number of shared publications:
Harry W. Herr
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
42 shared publications- Bernard H. Bochner
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
39 shared publications Guido Dalbagni
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York
35 shared publicationsPaul Russo
New York, NY
16 shared publicationsHarry Herr
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
14 shared publications- Andrew Julian Vickers
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA
10 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
Plasma cell-free DNA sequencing data
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
Plasma cell-free DNA sequencing data
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
Representativeness of Study Participants
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
Representativeness of Study Participants
- 2 February 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (8) , 1434-1444
Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
Purpose: Many patients with muscle-invasive bladder cancer (MIBC) are ineligible for cisplatin-based therapy. We conducted a phase II trial of neoadjuvant nivolumab ± ipilimumab for cisplatin-ineligible patients. Patients and Methods: Patients with MIBC were enrolled in two consecutive cohorts: (i) nivolumab alone and (ii) ipilimumab/nivolumab. A third cohort with alternative dosing was planned. The primary endpoint was eligibility for cystectomy ≤60 days after last treatment. Correlative analyses were performed, with the PURE-01 trial used as an independent dataset. Results: Fifteen patients enrolled onto each cohort. In cohorts 1 and 2, 12 of 15 and eight of 15 were eligible for cystectomy within 60 days, respectively. Due to cohort 2’s failure to meet the primary endpoint, cohort 3 was not initiated. With nivolumab alone, four patients achieved <ypT2ypN0 (26%), with two pathologic complete responses (pCR; 13%). With ipilimumab/nivolumab, three achieved <ypT2ypN0 (20%), with one pCR (7%). One patient after nivolumab and two after ipilimumab/nivolumab had durable clinical complete responses (CR) without cystectomy. Twelve-month recurrence-free survival (RFS) was 79% with nivolumab [95% confidence interval (CI), 61–100] and 61% with ipilimumab/nivolumab (95% CI, 39–95). Sequencing analyses suggest that NCOR1 alterations may be associated with improved clinical outcomes. Gene expression profiling indicated a potential association between tumor-infiltrating immune cells and longer RFS (log-rank P = 0.18); this was also observed in PURE-01 (P = 0.022). Conclusions: Among cisplatin-ineligible patients with MIBC, nivolumab alone was well tolerated. Ipilimumab/nivolumab caused toxicity that delayed cystectomy. Cases of progression before cystectomy indicated insufficient efficacy of pure neoadjuvant immunotherapy for unselected patients. Despite low response rates, some patients experienced sustained clinical CR without cystectomy.
- 2 February 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (8) , 1434-1444
Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
Purpose: Many patients with muscle-invasive bladder cancer (MIBC) are ineligible for cisplatin-based therapy. We conducted a phase II trial of neoadjuvant nivolumab ± ipilimumab for cisplatin-ineligible patients. Patients and Methods: Patients with MIBC were enrolled in two consecutive cohorts: (i) nivolumab alone and (ii) ipilimumab/nivolumab. A third cohort with alternative dosing was planned. The primary endpoint was eligibility for cystectomy ≤60 days after last treatment. Correlative analyses were performed, with the PURE-01 trial used as an independent dataset. Results: Fifteen patients enrolled onto each cohort. In cohorts 1 and 2, 12 of 15 and eight of 15 were eligible for cystectomy within 60 days, respectively. Due to cohort 2’s failure to meet the primary endpoint, cohort 3 was not initiated. With nivolumab alone, four patients achieved <ypT2ypN0 (26%), with two pathologic complete responses (pCR; 13%). With ipilimumab/nivolumab, three achieved <ypT2ypN0 (20%), with one pCR (7%). One patient after nivolumab and two after ipilimumab/nivolumab had durable clinical complete responses (CR) without cystectomy. Twelve-month recurrence-free survival (RFS) was 79% with nivolumab [95% confidence interval (CI), 61–100] and 61% with ipilimumab/nivolumab (95% CI, 39–95). Sequencing analyses suggest that NCOR1 alterations may be associated with improved clinical outcomes. Gene expression profiling indicated a potential association between tumor-infiltrating immune cells and longer RFS (log-rank P = 0.18); this was also observed in PURE-01 (P = 0.022). Conclusions: Among cisplatin-ineligible patients with MIBC, nivolumab alone was well tolerated. Ipilimumab/nivolumab caused toxicity that delayed cystectomy. Cases of progression before cystectomy indicated insufficient efficacy of pure neoadjuvant immunotherapy for unselected patients. Despite low response rates, some patients experienced sustained clinical CR without cystectomy.
- 1 December 2025
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 214 (6) , 591-600
Neoadjuvant Chemotherapy With Transurethral Resection for Bladder Preservation: 15-Year Follow-Up of the Retained Bladder
Bladder preservation is a desired goal for most patients with muscle invasive bladder cancer (MIBC), although select few are ideal candidates based on established criteria. Heterogenous cohorts with short follow-up hinder assessment of true risks/benefits for ideal candidates. We describe long-term outcomes in patients with MIBC, meeting established ideal criteria for bladder preservation, treated initially with systemic therapy and transurethral resection (TUR). Institutional retrospective review of 101 prospectively monitored patients meeting "ideal" criteria for bladder preservation achieving a clinical complete response to Cisplatin-based chemotherapy and TUR from 1994-2015, with >10 years follow-up. Primary endpoints were bladder-intact survival, local recurrence free survival, and cancer specific survival. Fifteen-year risk of death from bladder cancer was 11% (95% CI 5.8%, 18%), with the competing risk of death from other causes 44% (95% CI 33%, 54%), and cystectomy risk of 11% (95% CI 5.9%, 18%). Bladder preservation outcomes were near 40:40:10:10 for death from another cause, alive with an intact bladder; cystectomy; death from bladder cancer. Of 41 patients alive with their bladder intact, median (IQR) follow-up time was 14 (11, 20) years. One-third relapsed locally, with the probability persisting beyond 10 years, necessitating lifetime surveillance. Our findings may not be generalizable to other settings or to patients not meeting "ideal" criteria. Bladder preservation with neoadjuvant-chemotherapy with TUR is a viable option for select patients meeting established selection criteria. Patients and physicians must consider the probabilities of long-term bladder preservation versus excess mortality when electing bladder-sparing.
- 1 December 2025
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 214 (6) , 591-600
Neoadjuvant Chemotherapy With Transurethral Resection for Bladder Preservation: 15-Year Follow-Up of the Retained Bladder
Bladder preservation is a desired goal for most patients with muscle invasive bladder cancer (MIBC), although select few are ideal candidates based on established criteria. Heterogenous cohorts with short follow-up hinder assessment of true risks/benefits for ideal candidates. We describe long-term outcomes in patients with MIBC, meeting established ideal criteria for bladder preservation, treated initially with systemic therapy and transurethral resection (TUR). Institutional retrospective review of 101 prospectively monitored patients meeting "ideal" criteria for bladder preservation achieving a clinical complete response to Cisplatin-based chemotherapy and TUR from 1994-2015, with >10 years follow-up. Primary endpoints were bladder-intact survival, local recurrence free survival, and cancer specific survival. Fifteen-year risk of death from bladder cancer was 11% (95% CI 5.8%, 18%), with the competing risk of death from other causes 44% (95% CI 33%, 54%), and cystectomy risk of 11% (95% CI 5.9%, 18%). Bladder preservation outcomes were near 40:40:10:10 for death from another cause, alive with an intact bladder; cystectomy; death from bladder cancer. Of 41 patients alive with their bladder intact, median (IQR) follow-up time was 14 (11, 20) years. One-third relapsed locally, with the probability persisting beyond 10 years, necessitating lifetime surveillance. Our findings may not be generalizable to other settings or to patients not meeting "ideal" criteria. Bladder preservation with neoadjuvant-chemotherapy with TUR is a viable option for select patients meeting established selection criteria. Patients and physicians must consider the probabilities of long-term bladder preservation versus excess mortality when electing bladder-sparing.
- 13 April 2021
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 134 (5) , 816-817
Goal-directed Therapy and Postcystectomy Ileus: Reply
- 13 April 2021
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 134 (5) , 816-817
Goal-directed Therapy and Postcystectomy Ileus: Reply
- 17 August 2020
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 205 (2) , 483-490
Intraoperative Ureteral Stent Use at Radical Cystectomy is Associated with Higher 30-Day Complication Rates
Purpose:Radical cystectomy/urinary diversion is a high risk procedure. Intraoperative stents are commonly utilized to decrease ureteroenteric anastomosis related complications. Institutionally some...
- 17 August 2020
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 205 (2) , 483-490
Intraoperative Ureteral Stent Use at Radical Cystectomy is Associated with Higher 30-Day Complication Rates
Purpose:Radical cystectomy/urinary diversion is a high risk procedure. Intraoperative stents are commonly utilized to decrease ureteroenteric anastomosis related complications. Institutionally some...
- Open Access
- 1 April 2017
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 197 (4S) , e255
MP21-20 THE IMPACT OF PLASMACYTOID VARIANT HISTOLOGY ON SURVIVAL OF PATIENTS WITH UROTHELIAL CARCINOMA OF BLADDER AFTER RADICAL CYSTECTOMY
- 1 April 2017
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 197 (4S) , e255
Open AccessMP21-20 THE IMPACT OF PLASMACYTOID VARIANT HISTOLOGY ON SURVIVAL OF PATIENTS WITH UROTHELIAL CARCINOMA OF BLADDER AFTER RADICAL CYSTECTOMY
- Top Cited Papers
- 1 June 2015
- Published by Elsevier in European Urology
- Vol. 67 (6) , 1042-1050
Comparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial
- 1 June 2015
- Published by Elsevier in European Urology
- Vol. 67 (6) , 1042-1050
Top Cited PapersComparing Open Radical Cystectomy and Robot-assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial